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Abstract
A 62-year-old male was admitted because of lower left abdominal pain and diarrhea. The patient was diagnosed
with rectal cancer and multiple liver metastases. First, the laparoscopic Hartmann operation with a D3 lymph node
dissection was performed. After five cycles of folinic acid, 5-fluorouracil and oxaliplatin (FOLFOX) and bevacizumab,
and one additional FOLFOX, the tumor markers dramatically decreased; with carcinoembryonic antigen levels
ranging from 1096.3 to 7.6 ng/ml and carbohydrate antigen 19–9 levels ranging from 3248.0 to 42.1 U/ml. Computed
tomography showed a bilateral 14 colorectal liver metastases which indicated stable disease by the Response Evaluation
Criteria In Solid Tumors (RECIST) criteria and optimal morphologic response. A two-stage hepatectomy was performed to
complete a curative resection because of the insufficient remnant liver volume. Five partial hepatic resections in the left
liver and the right portal vein ligation were performed during the first operation. Thirty-four days later, a right
hepatectomy was successfully performed. Pathologically, there was tumor necrosis in 90 percent of the area
of the metastasized liver, and viable cells were detected in only a marginal part of the liver. The patient had
an uneventful postoperative course and was discharged fifteen days after the second operation. Uracil-tegafur
plus leucovorin was administered for 6 months as an adjuvant chemotherapy treatment. The patient is currently alive
and has remained disease-free for more than 5 years. In conclusion, an ideal combination of perioperative chemotherapy
and curative resection may provide a chance of long-term survival without recurrence of disease for selected patients
with more than ten bilateral colorectal liver metastases.
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Background
A large number of liver metastases have the greatest
impact on disease-free survival (DFS) and overall sur-
vival (OS) for patients with colorectal liver metastases
(CRLM) who underwent upfront hepatic resection [1].
Tumor number separation in patients with CRLM after
hepatic resection should be accomplished using the 1–4
and ≥5 classification [2]. Eight or more CRLM values
have shown significantly worse recurrence-free survival
(RFS) rates than CRLM values that are between 1 and 7
(28.7 % versus 13.6 %), partly due to a greater rate of
hepatic recurrence (57.7 % versus 37.1 %) [3]. In 102
CRLM patients with 8 or more tumors who underwent
upfront hepatectomy without chemotherapy, the 5-year
OS rate of 33 % was relatively good, but the 5-year RFS
rate was only 1.7 % [4].
Two-stage hepatectomy has been developed as a surgi-
cal modality for patients with multiple and bilateral
CRLM. Five-year RFS and median RFS values were only
11 % and 9.4 months, respectively, instead of 53 (87 %)
out of the 61 patients attempting the two-stage hepatec-
tomy and received the preoperative chemotherapy, and
20 (87 %) out of the 23 patients who received the
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interval chemotherapy and completed the two-stage hepa-
tectomy [5]. Induction chemotherapy renders curative re-
section for unresectable or marginally resectable patients
with CRLM [6, 7]; however, almost all patients with a large
number of CRLM live with recurrence. Herein, we report
a CRLM patient with 15 metastases who was treated with
effective induction chemotherapy and precise hepatic re-
section. He has remained alive and without any recur-
rence of disease for more than 5 years.
Case presentation
A 62-year-old male was admitted because of lower left
abdominal pain and diarrhea. The laboratory data on
admission showed a carcinoembryonic antigen (CEA)
level of 189.1 ng/ml and a carbohydrate antigen 19–9
(CA19-9) level of 723.0 U/ml (Table 1). Colonoscopy
showed stenosis by a rectal tumor. A magnetic resonance
imaging (MRI) showed colorectal cancer with swelling of
the primary lymph nodes and 15 bilateral CRLM (Fig. 1).
First, the laparoscopic Hartmann operation with a D3
lymph node dissection was performed for primary rectal
cancer. Pathologic diagnosis was moderately differentiated
tubular adenocarcinoma. The pathologic findings of upper
rectal cancer showed a tumor perforating to the surface of
the visceral peritoneum, three metastases in primary
lymph nodes, and a highly vascular space invasion. Final
stages were T4a, N1b, M1a, and Stage IV in the 7th revi-
sion of the AJCC/ UICC TNM staging system. We en-
rolled this patient into a clinical trial of the Kyushu study
group of clinical Cancer (KSCC0802 - UMIN000001308),
a phase II study of induction chemotherapy followed by
hepatic resection for unresectable or marginally resectable
CRLM patients [8]. Following 5 cycles of 5-fluorouracil
and oxaliplatin (FOLFOX) with bevacizumab, and one
cycle of FOLFOX, the CEA level decreased from 1096.3 to
7.6 ng/ml (normal range ≤3.4 ng/ml), and CA19-9 level
decreased from 3248.0 to 42.1 U/ml (normal range ≤37.0
U/ml). After the induction chemotherapy, a MRI showed
that the volume of CRLM slightly reduced and number of
those decreased from 15 to 14 (Fig. 2). However, it did not
show so called “early tumor shrinkage” that is associated
with long-term outcome in KRAS wild-type group-treated
chemotherapy plus cetuximab [9]. According to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) [10]
and the morphologic response criteria [11], the patient
was assessed as stable disease and had an optimal mor-
phologic response, respectively. The preoperative indocya-
nine green retention rate at a 15 min (ICG R 15) value
and the uptake ratio of the liver to the liver plus heart at
15 min (LHL 15) were 9.6 and 0.96, respectively. The right
hepatic resection rate was estimated to be 67.6 %. A two-
stage hepatectomy instead of a general hepatectomy was
thus conducted to complete a curative resection because
of the insufficient remnant liver volume. Five partial hep-
atic resections of the left liver metastases including left S1
tumor and the right portal vein ligation were performed
during the first stage. In the 2nd preoperative assessment,
percent remnant functional liver volume was increased
from 32.4 to 43.9 % by right portal vein ligation [12].
Thirty-four days after the first operation, a right hepatec-
tomy was successfully performed. The operation time and
blood loss was 295 min and 20 ml and 301 min and
435 ml, respectively, in the first and second operation. A
blood transfusion was never required. Although nine me-
tastases were resected, one metastasis had vanished by
chemotherapy. Pathologically, we observed tumor necrosis
in most of the area of the metastasized bilateral liver. Vi-
able cells were partially mixed in the 1st resected liver tis-
sues and were only present marginally in the 2nd resected
ones (Fig. 3). The background liver showed mild sinus-
oidal obstruction induced by oxaliplatin without steatosis
or steatohepatitis. The patient had an uneventful postop-
erative course and was discharged 15 days after the
resection. Uracil-tegafur plus leucovorin (UFT/LV)
was given for 6 months as an adjuvant chemotherapy
treatment. The patient is now alive more than 5 years and
without the recurrence of disease.
Discussion
This patient might have been initially resectable by two-
stage hepatectomy on admission; however, we avoided
upfront hepatectomy, which was decided to be oncologi-
cally unsuitable. A project study group of Japanese Society
of Hepato-Biliary-Pancreatic Surgery (JHBPS) nomogram
can make a preoperative prediction of the DFS of CRLM
treated with hepatic resection [1]. Six preoperative factors
Table 1 The laboratory data on admission
WBC 7.5 ×103/μl, BUN 11.2 mg/dl
RBC 4.95 ×106/μl Creatinine 0.63 mg/dl
Hemoglobin 16.3 g/dL Amylase 78 U/l
Hematocrit 48.6 % Cholinesterase 270 U/l
Platelet 259 ×103/μl Na 141 mEq/l
PT activity 101 % K 4.1 mEq/l
AST 21 U/l Cl 106 mEq/l
ALT 12 U/l CRP 0.38 mg/dl
ALP 428 U/l Glucose 91 mg/dl
LDH 245 U/l HbA1c 5.3 %
γ-GTP 20 U/l CEA 189.1 ng/ml
Total bile acid 0.6 μmol/l CA19-9 723.0 U/ml
Total protein 7.3 g/dl HBs-Ag (−)
Albumin 4.3 g/dl HCV-Ab (−)
WBC white blood cell, RBC red blood cell, PT prothrombin time, AST aspartate
aminotransferases, ALT alanine aminotransferases, ALP alkali phosphatase, LDH
lactate dehydrogenase, γ-GTP γ-glutamyltransferase, BUN blood urea nitrogen,
CRP C-reactive protein, CEA carcinoembryonic antigen, CA19-9 carbohydrate
antigen 19–9, HBs-Ag hepatitis B surface antigen, HCV-Ab anti-hepatitis C antibody
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were selected to create the nomogram for DFS: synchron-
ous metastases, 3 points; primary lymph node positive, 3
points; number of tumors 2–4, 4 points and ≥5, 9 points;
largest tumor diameter >5 cm, 2 points; extrahepatic me-
tastases at hepatectomy, 4 points, and preoperative CA19-
9 level >100 U/ml, 4 points. This patient was evaluated at
19 points out of a total of 25 points from the positive
variables of synchronous metastases, positive primary
lymph node, metastases ≥5, and a preoperative CA19-9
level of >100. The data were instantly calculated using the
DFS simulation program as a supplementary item. The
estimated 5-year DFS and median DFS for this patient
were quite low: 2 and 5.7 months, respectively. Neverthe-
less, the patient was able to survive without the recurrence
of disease for over 5 years.
We enrolled this patient into a phase II clinical trial
(KSCC0802) of induction chemotherapy followed by a
hepatic resection for unresectable or marginally resectable
CRLM [8]. Fourteen bilateral and scattered tumors were
detected even after 5 cycles of FOLFOX and bevacizumab,
followed by one cycle of FOLFOX. The tumor response
was determined as stable disease by the RECIST; however,
a b
c d
Fig. 1 Gd-EOB-DTPA-enhanced MRI on hepato-biliary-phase findings of CRLM upon admission. a–c A large number of bilateral CRLM were detected
on hepato-biliary-phase images of EOB-MRI as homogenous hypointensity. d The largest metastasis measured 2.5 cm in diameter on segment 5
a b
c d
Fig. 2 Gd-EOB-DTPA-enhanced MRI on hepato-biliary-phase findings of CRLM after the induction chemotherapy. a–d The volume of bilateral
CRLM slightly downsized and the tumor border turned to be clear on hepato-biliary-phase images of EOB-MRI
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tumor markers dramatically decreased before the first
hepatic resection. We have already reported that the
normalization of tumor marker levels after chemotherapy
was an important factor to obtain long-term survival after
induction chemotherapy and hepatectomy [13]. This
patient showed a distinct reduction of tumor markers by
induction chemotherapy; the CEA level decreased from
1096 to 7.6 ng/ml, and the CA19-9 level decreased from
3248 to 42.1 U/ml. During chemotherapy, the half-life of
CEA in this patient was 15 days, which is 20 days shorter
than normal and also an indication of good prognosis
[14]. Moreover, this patient showed an optimal morpho-
logic response, which has been positively correlated with
excellent OS rates, especially in patients with chemother-
apy and bevacizumab [11]. Bevacizumab in combination
with oxaliplatin/fluoropyrimidines can provide the highest
major pathological response rate [15], and the pathological





Fig. 3 Macroscopic and histological findings of the resected specimen. The fresh resected specimen on the 1st stage (a) and 2nd stage (b) hepatectomy
showed several whitish tumors with a sufficient surgical margin behind the normal liver. Almost all parts of the bilateral CRLM showed complete necrosis
(c, d) (H&E staining, objective; ×4, ×20); however, viable cells were detected only on marginal parts of the 2nd resected liver metastases (e). (H&E staining,
objective; ×20)
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correlate with improved survival [16]. In fact, this patient
showed a Grade 2 response, which is defined as either ne-
crosis or a disappearance of the tumor in >2/3 of the en-
tire tumor.
This case was performed by a conventional two-
stage hepatectomy in 2009. With another operation
procedure, the associating liver partition and portal
vein ligation for staged hepatectomy (ALPPS) may be
one of the techniques in this case; however, this tech-
nique requires enough attention because of having
high morbidity and mortality instead of a short-term
hypertrophy and high resectability rates [17]. In this
case, a traditional two-stage hepatectomy was success-
fully completed within a 34-day interval. Fortunately,
the tumor number did not increase between the two
operations. We observed no requirement of a blood
transfusion and no morbidity in both hepatic resections. A
large amount of intraoperative bleeding, a blood transfu-
sion, or a major complication can shorten the postopera-
tive survival rates [18, 19]. Although only six courses of
FOLFOX can increase the morbidity after a hepatic resec-
tion [20], the combinatorial use of bevacizumab may affect
the decrease of sinusoidal obstruction [21]. Fifty-seven
days after the second surgery, the administration of UFT/
LV was started and was continued for 6 months. The most
recently used adjuvant chemotherapy treatment with the
oral administration of UFT/LV for 6 months resulted in
significantly better RFS rates compared to the hepatic re-
section alone [22].
Conclusions
Suitable perioperative chemotherapy and curative hep-
atic resection may provide long-term survival rates with-
out the recurrence of disease for selected patients with a
large number of bilateral CRLM.
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